/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Allarity Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.12 -0.0917(-9.17%) ALLR at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 1.07
Highest Today 1.1839
Today’s Open 1.17
Prev. Close 1.2
52 Week High 2.06
52 Week Low 0.61
Day’s Range: Low 1.07 High 1.1839
52-Week Range: Low 0.61 High 2.06
1 day return -
1 Week return -17.24
1 month return -12.9
3 month return -37.93
6 month return +24.61
1 year return +0.46
3 year return -99.99
5 year return -
10 year return -

Institutional Holdings

Vanguard Institutional Extnd Mkt Idx Tr 0.61

XTX Topco Ltd 0.35

Geode Capital Management, LLC 0.35

Fidelity Extended Market Index 0.33

UBS Group AG 0.33

Jane Street Group LLC 0.18

Fidelity Total Market Index 0.15

Fidelity Series Total Market Index 0.15

Spartan Extended Market Index Pool F 0.11

Squarepoint Ops LLC 0.10

Spartan Total Market Index Pool G 0.05

Tower Research Capital LLC 0.02

Citigroup Inc 0.01

Bank of America Corp 0.00

Advisor Group Holdings, Inc. 0.00

Barclays PLC 0.00

Corsair Capital Management LLC 0.00

Goldman Sachs Group Inc 0.00

Morgan Stanley - Brokerage Accounts 0.00

Stonepine Capital Management Llc 0.00

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 17.28 M

PB Ratio 1.6456

PE Ratio 0.207

Enterprise Value 4.26 M

Total Assets 22.65 M

Volume 391212

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:120000 0.1M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:120000 0.1M

Annual Net worth FY23:-13017000 -13.0M, FY22:-16058000 -16.1M, FY21:-26648000 -26.6M, FY20:-5073000 -5.1M, FY19:-14400000 -14.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-12000 -0.0M, Q1/2025:-11000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-1000 -0.0M

Quarterly Net worth Q3/2025:-2806000 -2.8M, Q2/2025:-2320000 -2.3M, Q1/2025:-2732000 -2.7M, Q3/2024:-12152000 -12.2M, Q2/2024:-1629000 -1.6M

Fund house & investment objective

Company Information Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 6

Industry Biotechnology

CEO Mr. Thomas H. Jensen

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow